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Introduction
The gastrointestinal (GI) tract of vertebrates harbors a complex microbial community that provides essential function for the host (Nordgard et al., 2005) . The mucosal surface of the human gut is colonized by approximately 10 14 bacteria (Suau et al., 1999) with 400 different species (Gorbach, 1996) . The composition and distribution of gut bacteria demonstrate high intra-and inter-individual variability in humans and is susceptible to changes in composition with age, diet, GI transit time and disease state. The majority of gut microbiota colonize the colon, where there is very slow motility and low oxidation-reduction potential. This contributes to the fact that 99% of colonic microbiota are obligate anaerobes (Hao and Lee, 2004) .
Gut bacteria are responsible for the biotransformation of many endogenous and exogenous molecules, usually involving their breakdown via hydrolysis, de-conjugation or reduction (Sousa et al., 2008) . There are several examples of commercially available drugs that are metabolized by gut bacteria with extensive reviews provided by Hartiala (1973) and Sousa et al. (2008) . Sousa et al. (2008) suggested that the recent increase in focus on metabolism mediated by gut bacteria correlates with the increase in drugs reaching the market with extended release formulations, or lower permeability and solubility. In addition, drug-drug interactions can be a concern, especially for drugs that affect the composition of the microbiota, which can potentially alter the metabolism of a concomitantly administered substrate for bacterial biotransformation. Drug-drug interactions can also be mediated through metabolites produced by gut bacteria. Sorivudine, an antiviral drug released in the Japanese market in 1993, was withdrawn due to a fatal drug-drug interaction between a gut metabolite of sorivudine and the anti-cancer drug 5-fluorouracil (Okuda et al., 1998) .
There are a number of challenges in evaluating the involvement of gut bacteria in drug metabolism. A drug can be incubated in vitro with intestinal content, fecal samples or isolated microbes (O'Sullivan, 2000) , but there are several shortcomings with these methods. For example, fecal samples may not accurately reflect the actual active proportion of microbes over the entire length of the gut in vivo (Finegold et al., 1983) and it has been suggested that only 25% of intestinal bacteria are cultivable (Bartosch et al., 2004) . In vivo evaluation of gut bacterial metabolism in animals is feasible. However, the limitations of large interspecies differences in microbiota composition and distribution have to be taken into consideration (Rowland et al., 1986; Sousa et al., 2008) . Pseudo-germ free (pGF) rats can be created by treatment with broadspectrum antibiotics and have helped in elucidating the role of gut bacteria in the metabolism of drugs (Jin et al., 2010; Lee et al., 2012; Liu et al., 2012; Yoo et al., 2014) .
Deleobuvir is a potent inhibitor of the hepatitis C virus (HCV) NS5B polymerase. In a human Phase Ia study in healthy male volunteers, deleobuvir was found to undergo extensive reduction to form a major circulating metabolite, CD 6168 ( Fig. 1) , which was confirmed later in a human ADME (absorption, distribution, metabolism and excretion) study (Chen et al., 2015) .
In 14 C-deleobuvir ADME studies in rats, CD 6168 was also found in the feces and accounted for approximately 43% of the administered dose (data on file, Boehringer Ingelheim Pharmaceuticals, Inc.). Interestingly, in bile-cannulated rats, CD 6168 represented only 3% of the radioactive dose recovered in the bile. This observation, together with the fact that CD 6168 is a reduction product of the parent molecule, suggested that gut bacteria might be involved in the formation of CD 6168.
As previously mentioned, methodologies to evaluate gut bacteria metabolism are associated with several caveats. Therefore, the studies reported herein use a combination of in vitro
This article has not been copyedited and formatted. The final version may differ from this version. anaerobic incubations with rat and human feces and an in vivo antibiotic-treated (pseudo-germ free) rat model to confirm the role of gut bacteria in the formation of CD 6168 from deleobuvir.
In addition, since in vitro studies for gut bacterial metabolism generally only provide a qualitative answer for the extent of metabolism observed in vivo, we have attempted to use a scaling approach to provide a more quantitative result. The advantages and limitations of these approaches are discussed.
Materials and Methods
Chemicals, Reagents and Other Materials
Deleobuvir, CD 6168, 
Incubation of deleobuvir with rat or human feces
Individual fecal samples from three untreated male rats and also two healthy male human volunteers were collected and immediately transferred to an anaerobic chamber with oxygen <5 ppm atmosphere (Coy Laboratory Products, Inc., Grass Lake, MI). All of the in vitro processes up to analysis by LC-MS/MS were carried out under anaerobic conditions. Fecal samples were mixed with Dulbecco's phosphate-buffered saline containing 20 mM of glucose to obtain a concentration of 0.05 g/mL (weight of fecal sample/volume of buffer). Samples were then homogenized and centrifuged at 500 rpm for 5 min at 4 o C to remove debris. Processed aliquots were pre-incubated for 5 min at 37 ºC and reactions were initiated by the addition of deleobuvir (100 µM, final concentration). Reactions were terminated at 0, 5, 10, 20, 30, 60, 90 and 120 min by removing an aliquot of incubate and adding quench solution containing 80%
acetonitrile with 13 C 6 -CD 6168, as an internal standard. Sealed samples were removed from the anaerobic chamber and analyzed by LC-MS/MS for levels of CD 6168. antibiotic administration to these pseudo-germ free rats (pGF rats).
Pseudo-germ free rat study
Drug administration:
Deleobuvir was administered as a single oral dose of 10 mg/kg (25% PEG 400, 3% Tris and 72% water) to 10 rats. In parallel, a positive control was used to validate the in vivo methodology. Hesperidin, which is a known substrate for gut bacterial metabolism (Garg et al, 2001 ), was administered orally as a single dose of 50 mg/kg to 10 rats. Hesperidin dosing solution contained 47% PEG 400, 3% DMSO and 50% water.
Collection and bioanalysis of plasma and fecal samples:
Blood samples were collected from a tail vein using capillary microsampling technique at pre-dose, and 1, 2, 4, 6, 8, and 24 hours after dosing. Briefly, a 50 µL minivette (Sarstedt AG& Co; Hofstraße, Nümbrecht, Germany) coated with K 3 EDTA was placed at the hub and filled to volume and dispensed into 0.25 mL microcentrifuge tubes (VWR; Radnor, PA). Samples were centrifuged at 4 °C. An exact 20 µL volume of plasma from each sample was dispensed into a microtube and stored at -20 °C until analysis.
Plasma protein was precipitated by the addition of 95% acetonitrile containing 13 C 6 -deleobuvir (2004) . Briefly, plasma samples were diluted 4-fold with 50 mM potassium phosphate buffer (pH 7.2) containing β -glucuronidase (1.6 U). Samples were then incubated at 55°C for 60 min and the reaction was terminated by the addition of quench solution containing internal standard.
Analytes were quantified using calibration curves, which were processed similarly to plasma samples.
Rats were housed in metabolism cages prior to drug administration. During 14 C-ADME study in rats, large majority of the radioactive dose (84%) was recovered in feces within 48 h. Hence, feces from individual rats were collected in sterile vials at pre-dose, 24 and 48 h. Samples were homogenized following the addition of 50% isopropanol/water (v/v) at 3 mL/g. Approximately 1 g of fecal homogenate was extracted with 1% formic acid containing 13 C 6 -deleobuvir and 13 C 6 -CD 6168 (deleobuvir subgroup) or 70% methanol with d 3 -hesperetin (hesperidin subgroup) in acetonitrile. Fecal pellets were further extracted twice without internal standard. Extracts were combined and evaporated to dryness under a nitrogen stream at room temperature. Samples were reconstituted with 0.1% acetic acid, 40% water in acetonitrile. Aliquots were analyzed by LC-MS/MS for hesperidin, hesperetin, deleobuvir and CD 6168 levels.
LC-MS/MS and chromatographic conditions
For deleobuvir and CD 6168, an SIL5000 autosampler (Shimadzu, Columbia, MD) and LC-10AD vp Binary Pump (Shimadzu) connected to a Sciex 4000 Q Trap mass spectrometer (Applied Biosystems/Sciex, Thornhill, Ontario, Canada) were used. Samples were separated on a Gemini C 18 column (50 × 2.0 mm) (Phenomenex, Torrance, CA) with a 5 µm particle size. This article has not been copyedited and formatted. The final version may differ from this version. connected to a Sciex 5500 Q Trap mass spectrometer (Applied Biosystems/Sciex) was used. An Acquity C 18 column (Waters Corporation) (50 × 2.1 mm) was used with 1.7 µm particle size. 
Data analysis
In vitro-in vivo correlation. The extent of in vivo formation of CD 6168 by gut bacteria was extrapolated from in vitro incubations based on the following process: In vitro formation rate (nmol of metabolite formed/mL/min) was determined based on the slope of metabolite formation over the initial linear range. The metabolite formation rate was then normalized by the fecal density in the incubation (g of feces/mL of incubation) to obtain the formation rate with a unit of nmol of metabolite formed/ g of feces/min. The total amount of metabolite formed in the gut (Metabolite gut ) was estimated using equation 1.
Eq.1
For rats, the weight of cecal content was 2.9 g and for human the weight of feces was 110 g (Rowland et al., 1986) . The average colonic transit time was 6 h for rats (de Zwart et al., 1999) and 24 h for humans (Wilson, 2000) . 
Results
In vitro metabolism of deleobuvir by HLM or HLC
Deleobuvir (0.1, 1, 10 µM) was stable with both HLM and HLC up to 120 min of incubation, in the presence and absence of NADPH and NADH (data not shown). No quantifiable levels of CD 6168 were detected (LLOQ of 7.8 nM, which would represent 0.078% conversion of 10µM deleobuvir).
In vitro metabolism of deleobuvir with rat or human fecal homogenates
Preliminary studies were conducted to establish linearity with respect to time and deleobuvir concentration up to 100 µM for the formation of CD 6168 (data not shown). Incubation of deleobuvir (100 µM) with rat fecal homogenate generated CD 6168 at a rate of 3.18 ± 2.05 nmol/min/g of fecal content (average of 3 animals; Fig. 2A ). With human fecal homogenate, under similar incubation conditions, the formation rates of CD 6168 were 1.95 nmol/min/g and 0.184 nmol/min/g of fecal content for subject I and subject II, respectively (Fig. 2B) .
Validation of pseudo-germ free rat model
The mean plasma concentration-time profiles of total hesperetin (hesperetin and hydrolyzed hesperetin-glucuronide), after administration of 50 mg/kg of hesperidin to control and pGF rats, are illustrated in Fig. 3 . As shown in Table 1 , t max values ranged from 6-8 h for control rats and 4-8 h for pGF rats. The AUC 0-∞ values of hesperetin were 5-fold higher in control (3,454 ± 760 ng·h/mL) compared to pGF rats (685 ± 368 ng·h/mL).
The cumulative amounts of hesperidin and hesperetin excreted in feces up to 48 h post-dose are shown in Fig. 4 . Slightly higher levels of hesperidin were excreted by pGF rats (12 ± 5% of dose) compared to control rats (7.8 ± 3.4 % of dose). This finding was also reflected in the lower
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This article has not been copyedited and formatted. The final version may differ from this version. levels of hesperetin excreted by pGF rats (0.9 ±0.3% of parent dose) compared to control rats (2.4 ± 1.6 % of parent dose). The excretion of both hesperidin and hesperetin in pGF rats was statistically significant (P<0.05) compared to control.
Metabolism of deleobuvir in pseudo-germ free rats
The mean plasma concentration-time profiles of deleobuvir and CD 6168 are presented in Fig. 5A and 5B, respectively, following the administration of 10 mg/kg deleobuvir to control and pGF rats. Pharmacokinetic parameters are summarized in Table 2 . Deleobuvir was rapidly absorbed in both control and pGF rats, with t max values of 1 h for both groups. Comparable plasma exposure (AUC 0-∞ ) was observed for deleobuvir in control rats (63,438 ± 18,181 ng·h/mL) and pGF rats (66,683 ± 21, 253 ng·h/mL). In addition, although plasma levels of CD 6168 were relatively low compared to the parent (representing 0.7% of parent C max and 2.1% of parent AUC), levels of CD 6168 were much higher in control rats (C max of 114 ± 65 ng/ml and AUC of 1, 312 ± 649 ng·h/mL) compared to pGF rats (C max of 15.5± 7.7 ng/ml and AUC of 146 ± 64 ng·h/mL). The cumulative amounts of deleobuvir and CD 6168 excreted in feces over 48 h in both control and pGF rats are presented in Fig. 6A(deleobuvir) and Fig. 6B (CD 6168). Substantially higher levels of deleobuvir were excreted in feces of pGF rats (105 ± 21% of dose) compared to control rats (26 ± 15% of dose). In addition, CD 6168 accounted for 1.5 ± 1.3 % of the deleobuvir dose in pGF rats, compared to 42 ± 8% in control rats.
In vitro to in vivo extrapolation based on fecal incubations
Based on in vitro formation rates and the assumptions inherent in these calculations (as outlined in Methods and Discussion), the total amount of CD 6168 estimated to be formed from deleobuvir (using Eq. 1) was 2.18 ± 1.40 mg in rats and 201 mg (subject I) and 19.0 mg (subject II) in humans. These numbers were compared to in vivo levels of CD 6168 excreted into feces,
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This article has not been copyedited and formatted. The final version may differ from this version. Table 3 . For rats, the amount of CD 6168 excreted into feces was 1.5 ± 0.3 mg (data derived from control rats in the pseudo-germ free rat study). For human, the amount of CD 6168 excreted into feces was 280 mg (35% of a 800 mg dose) (Chen et al., 2015) .
Discussion
The overall role of the gut microbiome in health and disease is increasingly being appreciated (Owyang and Wu, 2014; Ursell et al., 2014; Yip and Chen, 2015; Klaassen and Cui 2015) , as is the contribution of gut bacteria to the metabolism of drugs (Sousa et al., 2008) . Our own experience with BILR 355 (Li et al., 2012) and deleobuvir, reported here, has also underlined an important role of gut bacteria in the pre-systemic conversion of parent drug.
For deleobuvir, the substantial presence of a reduced metabolite, CD 6168, in rat feces but not in bile in a rat 14 C-ADME study, suggested that CD 6168 was likely formed by gut bacteria.
While reductive reactions can be carried out by other drug metabolizing enzymes, including cytochrome P450 (Guengerich, 2001) , these are relatively rare. In addition, in vitro incubations of deleobuvir with human liver microsomes and cytosol did not generate CD 6168. Anaerobic incubations with deleobuvir, using rat and human fecal homogenates, demonstrated substantial formation of CD 6168. The enzymes responsible for reduction can be sensitive to the presence of oxygen and as such it was important to adopt appropriate in vitro conditions. An anaerobic chamber was instrumental to these studies (Finegold et al., 1983; Kang et al., 2013) .
To assess whether the plasma levels of CD 6168 could arise from bacterial biotransformation, the in vitro formation rate of CD 6168 was used to extrapolate the amount of CD 6168 which could be formed in vivo, with a number of assumptions (see below), and which was compared to levels of CD 6168 in the human feces) and the total number of bacteria in the GI tract. However, these numbers are not readily available and at best are approximations. This highlights the necessity to better characterize the gut microbiome. In this study, the two volunteers generated very different levels of CD 6168, which emphasizes a challenge with this approach. Clearly, due to inherent variability in gut bacterial metabolism, several human fecal donor samples should be tested for a more robust measure of IVIVE. Interspecies differences in CD 6168 oxidation adds additional challenges for a cross species IVIVE using a single approach. However, for both human and rat, the goal was to determine whether bacterial biotransformation could possibly account for large circulating levels of CD 6168. Considering the limitations of this IVIVE, we believe that this goal was achieved, although generating accurate IVIVE for such mechanisms needs further work in the field of microbiome. A pseudo-germ free (pGF) rat model was also investigated to assess the importance of gut bacterial biotransformation in the disposition of deleobuvir. There can be substantial species differences in specificity and substrate selectivity for drug metabolizing enzymes between rats and humans (Martignoni et al., 2006) . Similarly, species differences in gut microbiota (Rowland et al., 1986 ) make inter-species extrapolations difficult. Germ-free rats have been used to
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This article has not been copyedited and formatted. The final version may differ from this version. There are significant challenges in the maintenance and use of germ-free animals (Gordon and Pesti, 1971) . Pre-treatment of animals with antibiotics can provide a temporary, almost complete microbe free animal model (Sousa et al., 2008; Kang et al., 2013) . This simpler pGF rat model was validated in our studies using a known probe for gut bacterial metabolism, hesperidin. The pharmacokinetic parameters obtained for hesperetin in this study (Table 1) were comparable to data reported by Jin et al. (2010) . The pGF rats excreted significantly higher levels of hesperidin compared to control rats, consistent with the lack of conversion of hesperidin to hesperetin by gut bacteria (Fig. 4) . Similarly, the plasma exposure of the metabolite, hesperetin, was significantly higher in control compared to pGF rats (Fig. 3) . The flavonoid backbone of hesperetin is further degraded by gut bacteria into numerous phenolic and carboxylic acid products (Garg et al, 2001 ) which explains the low levels of hesperetin in feces of pGF and control rats (<3% of dose).
Although formation of CD 6168 in rats, compared to humans, is a relatively less abundant metabolic pathway, these findings in pGF rats support a key role of gut bacteria in the formation of CD 6168 from deleobuvir. CD 6168 exposure levels were significantly lower in pGF rats with an average AUC 0-∞ of 146 ± 64 ng·h/mL ( Fig. 5B and Table 2 ), compared to control rats, 1,312 ± 649 ng·h/mL. About 1.5 mg (42 % of dose) of CD 6168 was excreted in feces of control rats, but a mere 0.06 mg (1.51 % of dose) was found in feces of pGF rats. Conversely, significantly higher levels of deleobuvir were excreted into feces in pGF rats (105% of dose) compared to control rats (26 % of dose), confirming the role of gut bacteria in the biotransformation of deleobuvir. For deleobuvir, the plasma exposure levels were similar in both
This article has not been copyedited and formatted. The final version may differ from this version. rat groups but significantly different in amount excreted into feces. The amount of deleobuvir excreted into feces is a combination of unabsorbed drug (60% bioavailability) with the amount excreted into bile as deleobuvir and deleobuvir-glucuronide.
Deleobuvir, as well as CD 6168, were rapidly absorbed with a t max of approximately 3 hours.
Both exhibited similar pharmacokinetics and high variability (Chen et al, 2015) , but there was no clear inverse correlation of deleobuvir and CD 6168 exposure in vivo. This suggests that while the variability in gut bacteria between humans may account for some of the variability in plasma exposure, other aspects of differential clearance between the two compounds, i.e. further metabolism of CD 6168 versus direct glucuronidation of deleobuvir may also play a role.
Overall, using appropriate in vitro and in vivo tools of gut bacterial metabolism offers experimentally viable approaches to identify a role for gut bacteria in the metabolism of a drug.
Attempts at IVIVE, taking the rate of metabolite formation in feces and scaling to the amount of gut bacterial metabolite formed in vivo, may offer a way to assess the contribution by gut bacteria to the overall biotransformation, with awareness of inter-individual variability and the complex nature of the GI tract.
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